

Comparison of dual-chamber pacing versus septal myectomy in patients with hypertrophic obstructive cardiomyopathy¹¹There is no conflict of interest to disclose with respect to this article.

Journal of the American College of Cardiology
34, 191-196

DOI: 10.1016/s0735-1097(99)00173-4

Citation Report

#	ARTICLE	IF	CITATIONS
3	Dual Chamber Pacing for Patients With Hypertrophic Obstructive Cardiomyopathy: A Clinical Perspective in 2000. Mayo Clinic Proceedings, 2000, 75, 173-180.	1.4	23
4	Analysis of dual-chamber pacing as a treatment for refractory limiting symptoms in patients with obstructive hypertrophic cardiomyopathy. Current Cardiology Reports, 2000, 2, 131-133.	1.3	0
5	Emerging indications for permanent pacing. Current Cardiology Reports, 2000, 2, 353-360.	1.3	3
6	Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Clinical Research in Cardiology, 2000, 89, IV41-IV54.	1.2	29
7	Dual Chamber Pacing for Patients With Hypertrophic Obstructive Cardiomyopathy: A Clinical Perspective in 2000. Mayo Clinic Proceedings, 2000, 75, 173-180.	1.4	27
8	To ablate or operate? that is the question!**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2001, 38, 1707-1710.	1.2	22
9	Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 2001, 38, 1701-1706.	1.2	213
10	Outcomes of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery ¹¹ Supported, in part, by grant NCC9-60 from the National Aeronautics and Space Administration, Houston, Texas, Grant #9951522V from the American Heart Association Ohio Local Chapter, Columbus, Ohio and Grant #R01 HL56688-01A1 from the National Institutes of Health, Bethesda, Maryland. ²² Presented, in part, at the 49th Annual Scientific Sessions of American Coll. Journal of the American College of Cardiology, 2001, 38, 1994-2000.	1.2	190
12	Cardiac Pacing. Medical Clinics of North America, 2001, 85, 369-421.	1.1	35
13	Pacing and Hypertrophic Cardiomyopathy. American Journal of the Medical Sciences, 2001, 322, 156-159.	0.4	1
14	Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2001, 16, 58-65.	0.8	9
15	Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2002, 287, 1308-20.	3.8	1,981
16	Dual Chamber Pacing in Hypertrophic Cardiomyopathy: Long-Term Effects on Diastolic Function. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1433-1440.	0.5	24
17	Hypertrophic cardiomyopathy: state-of-the-art review, with focus on the management of outflow obstruction. Internal Medicine Journal, 2003, 33, 521-529.	0.5	18
18	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 1687-1713.	1.2	1,444
19	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. European Heart Journal, 2003, 24, 1965-1991.	1.0	448
20	Unusual Indications for Cardiac Pacing. , 0, , 32-43.		0
21	Hypertrophic cardiomyopathy. Current Problems in Cardiology, 2004, 29, 239-291.	1.1	46

#	ARTICLE	IF	CITATIONS
23	Schrittmachertherapie der hypertrophisch obstruktiven Kardiomyopathie. Herzschrittmachertherapie Und Elektrophysiologie, 2004, 15, i47.	0.3	0
24	The case for surgery in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2044-2053.	1.2	204
25	Hypertrophic Obstructive Cardiomyopathy. New England Journal of Medicine, 2004, 350, 1320-1327.	13.9	276
26	Septal Myectomy Results in Regression of Left Ventricular Hypertrophy in Patients With Hypertrophic Obstructive Cardiomyopathy. Annals of Thoracic Surgery, 2004, 78, 2118-2122.	0.7	68
27	A New Strategy for the Attenuation of Left Ventricular Pressure Gradient in Patients with HOCM. Internal Medicine, 2004, 43, 273-274.	0.3	0
29	Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy. Circulation, 2005, 111, 2033-2041.	1.6	297
30	Effect of Biventricular Pacing on Left Ventricular Outflow Tract Pressure Gradient in a Patient with Hypertrophic Cardiomyopathy and Normal Interventricular Conduction. Journal of Cardiovascular Electrophysiology, 2006, 17, 207-209.	0.8	18
31	Long-Term Effects of Dual-Chamber Pacing With Periodic Echocardiographic Evaluation of Optimal Atrioventricular Delay in Patients With Hypertrophic Cardiomyopathy >50 Years of Age. American Journal of Cardiology, 2006, 97, 1769-1775.	0.7	41
32	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy. Progress in Cardiovascular Diseases, 2006, 49, 123-151.	1.6	45
33	Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. European Heart Journal, 2007, 28, 2256-2295.	1.0	677
34	Surgery Insight: septal myectomy for obstructive hypertrophic cardiomyopathy—the Mayo Clinic experience. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 503-512.	3.3	120
35	Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Circulation, 2007, 116, 196-206.	1.6	160
36	Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart, 2007, 94, 1276-1281.	1.2	58
37	Most Fully Informed Patients Choose Septal Ablation Over Septal Myectomy. Circulation, 2007, 116, 207-216.	1.6	79
38	Guía de práctica clínica sobre marcapasos y terapia de resincronización cardíaca. Revista Española De Cardiología, 2007, 60, 1272.e1-1272.e51.	0.6	6
39	Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. Europace, 2007, 9, 959-998.	0.7	278
40	Does Myectomy Convey Survival Benefit in Hypertrophic Cardiomyopathy?. Heart Failure Clinics, 2007, 3, 275-288.	1.0	16
41	Evolving Indications for Pacing: Hypertrophic Cardiomyopathy, Sleep Apnea, Long QT Syndromes, and Neurally Mediated Syncope Syndromes * *This study was supported in part by grant 73-1976 from the Canadian Institute for Health Research (CIHR).. , 2007, , 473-498.		0

#	ARTICLE	IF	CITATIONS
43	Clinical and Echocardiographic Variables Fail to Predict Response to Dual-Chamber Pacing for Hypertrophic Cardiomyopathy. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 796-800.	1.2	14
44	Management of Symptoms in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2008, 117, 429-439.	1.6	121
45	Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. <i>Heart</i> , 2010, 96, 352-356.	1.2	63
46	Device therapy in hypertrophic cardiomyopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1767-1775.	0.6	4
47	Biventricular pacing in hypertrophic obstructive cardiomyopathy: A pilot study. <i>Heart Rhythm</i> , 2011, 8, 221-227.	0.3	34
48	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011, 58, e212-e260.	1.2	984
49	Long-Term Survival in Patients With Resting Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2313-2321.	1.2	140
50	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2703-2738.	1.2	252
51	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2011, 124, e783-831.	1.6	1,039
52	Unmasking the truth. <i>BMJ Case Reports</i> , 2011, 2011, bcr0720103193-bcr0720103193.	0.2	0
53	Effect of Cardiac Resynchronization on Gradient Reduction in Patients with Obstructive Hypertrophic Cardiomyopathy: Preliminary Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1544-1552.	0.5	17
54	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1303-1338.	0.4	73
55	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, e153-e203.	0.4	260
56	Hypertrophic Cardiomyopathy. <i>Current Problems in Cardiology</i> , 2011, 36, 409-453.	1.1	25
57	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. <i>Circulation</i> , 2011, 124, 2761-2796.	1.6	725
58	Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. <i>The Cochrane Library</i> , 2021, 2021, CD008523.	1.5	24
59	Biventricular / Left Ventricular Pacing in Hypertrophic Obstructive Cardiomyopathy: An Overview. <i>Indian Pacing and Electrophysiology Journal</i> , 2012, 12, 114-123.	0.3	5
60	Patient selection for alcohol septal ablation for hypertrophic obstructive cardiomyopathy: clinical and echocardiographic evaluation. <i>Interventional Cardiology</i> , 2012, 4, 349-359.	0.0	3

#	ARTICLE	IF	CITATIONS
61	The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. <i>Heart</i> , 2012, 98, 116-125.	1.2	146
62	Potential Role of Biventricular Pacing Beyond Advanced Systolic Heart Failure. <i>Circulation Journal</i> , 2013, 77, 1364-1369.	0.7	13
64	Comparison of Long-Term Effect of Dual-Chamber Pacing and Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy. <i>Scientific World Journal, The</i> , 2013, 2013, 1-7.	0.8	5
66	Long-Term Benefit of Myectomy and Anterior Mitral Leaflet Extension in Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015, 115, 670-675.	0.7	63
67	Optimized pacing mode for hypertrophic cardiomyopathy: Impact of ECG fusion during pacing. <i>Heart Rhythm</i> , 2015, 12, 909-916.	0.3	9
69	Sequential Atrioventricular Pacing in Patients With Hypertrophic Cardiomyopathy: An 18-year Experience. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 377-383.	0.4	8
70	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2016, 9, e002764.	1.6	51
71	Role of Exercise Testing in Hypertrophic Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1374-1386.	2.3	68
72	Short atrioventricular delay pacing therapy in young and old patients with hypertrophic obstructive cardiomyopathy: good long-term results and a low need for reinterventions. <i>Europace</i> , 2018, 20, 1683-1691.	0.7	8
73	Predictors of exercise capacity following septal myectomy in patients with hypertrophic cardiomyopathy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1066-1073.	0.8	10
74	Echocardiographic tissue imaging evaluation of myocardial characteristics and function in cardiomyopathies. <i>Heart Failure Reviews</i> , 2021, 26, 813-828.	1.7	2
75	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	1.0	899
76	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	0.7	370
79	Outpatient Therapy. <i>Developments in Cardiovascular Medicine</i> , 2000, , 149-200.	0.1	0
80	Title is missing!. <i>Japanese Journal of Electrocardiology</i> , 2002, 22, 42-56.	0.0	0
81	Advances in cardiac pacing. <i>Acta Cardiologica</i> , 2003, 58, 101-117.	0.3	0
82	Echocardiography in the Evaluation and Management of Patients with Hypertrophic Cardiomyopathy. , 2007, , 653-678.		0
85	Arrhythmias and Hypertrophic Cardiomyopathy. , 2014, , 253-264.		0

#	ARTICLE	IF	CITATIONS
87	Contemporary treatment of hypertrophic cardiomyopathy. Texas Heart Institute Journal, 2009, 36, 194-204.	0.1	37
88	Midterm Outcome of Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy (HOCM): A Single-Center Observational Study. Heart Surgery Forum, 2020, 23, E873-E879.	0.2	1
89	Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten?. Asian Cardiovascular and Thoracic Annals, 2022, , 021849232210744.	0.2	0
92	United States Perspectives on the Role of Dual-Chamber Pacing in Patients With Hypertrophic Cardiomyopathy. , 0, , 236-245.		0
93	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Translation of the document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2022, 64, 7-86.	0.1	1
94	Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review. Journal of Clinical Medicine, 2022, 11, 3405.	1.0	5
95	Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	24
96	Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature. ESC Heart Failure, 0, , .	1.4	2
97	Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis “ 2023. Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.3	1